<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45168">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01829126</url>
  </required_header>
  <id_info>
    <org_study_id>HEALTH-F5-2012-305495-OT5</org_study_id>
    <nct_id>NCT01829126</nct_id>
  </id_info>
  <brief_title>Development and Prevention of Severe Heart Disease in Systemic Sclerosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gabriele Valentini</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Paris 5 - Rene Descartes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Florence</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Basel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pecs</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Schoen Klinik Hamburg Eilbek</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second University of Naples</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <authority>Germany: Ethics Commission</authority>
    <authority>Hungary: Institutional Ethics Committee</authority>
    <authority>France: Institutional Ethical Committee</authority>
    <authority>Switzerland: Ethikkommission</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic sclerosis is an orphan, multiorgan disease affecting the connective tissue of the
      skin and all internal organs. Cardiac involvement, mainly characterised by small
      intramyocardial coronary artery involvement and myocardial fibrosis, can cause the
      development of impaired diastolic ventricular filling, cardiac blocks and ventricular
      arrhythmias, and can ensue in  congestive heart failure and sudden death. Until now, no drug
      has been proven to have a therapeutic effect on SSc myocardial disease on an evidence-based
      level. Short-term trials and retrospective studies have suggested a favourable and
      protective effect of calcium channel blockers and angiotensin converting enzyme inhibitors
      in patients with myocardial involvement. However, no data are presently available on the
      prevention and treatment of severe heart disease.

      This observational trial is part of the collaborative project &quot;DeSScipher&quot;, one out of five
      observational trials to decipher the optimal management of systemic sclerosis. Aim of this
      observational trial is to assess the efficacy and safety of calcium channel blockers and
      angiotensin converting enzyme inhibitors in asymptomatic SSc patients with cardiac
      involvement.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Cumulative incidence of CB, VA, pacemaker implantation, congestive heart failure and sudden death</measure>
    <time_frame>1 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cumulative incidence of cardiac blocks, ventricular arrhythmias, pacemaker implantation, congestive heart failure and sudden death.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Incidence of drug-related adverse events, incidence of withdrawal from treatment due to drug-related adverse events</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">765</enrollment>
  <condition>Systemic Sclerosis</condition>
  <condition>Cardiac Diseases</condition>
  <condition>Heart Block</condition>
  <condition>Cardiac Arrhythmia</condition>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>CCB</arm_group_label>
    <description>Patients receiving calcium channel blockers (CCB)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACEi</arm_group_label>
    <description>Patients receiving angiotensin converting enzyme inhibitors (ACEi)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CCB and ACEi</arm_group_label>
    <description>Patients receiving calcium channel blockers (CCB) and angiotensin converting enzyme inhibitors (ACEi)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <description>Patients not receiving calcium channel blockers (CCB) and/or angiotensin converting enzyme inhibitors (ACEi)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population are adult and juvenile SSc patients from the EUSTAR cohort
        (MEDSonline database) and the jSScWG cohort
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Juvenile and adult systemic sclerosis patients, with diagnosis according to the SSc
             ACR/EULAR criteria or the PRES/ACR/EULAR juvenile SSc criteria respectively

          -  Asymptomatic (for cardiac disease) systemic sclerosis patients at risk for severe
             heart disease with at least one of the following risk factors: male sex and/or DLCO
             lower than 80% and/or sPAP &gt; 30 mmHg and/or synovitis and/or joint contractures
             and/or digital ulcers and/or proteinuria.

        Asymptomatic for cardiac disease is defined by patients without dyspnea NYHA &gt;/= II,
        without palpitations and without bilateral leg edema.

        Exclusion Criteria:

          -  Any significant pulmonary parenchymal (FVC &lt; 70% and/or DLCO &lt; 70%), pulmonary
             vascular (estimated systolic PAP &gt; 40 mmHg), gastrointestinal (malabsorption syndrome
             or paralytic ileus) or renal (serum creatinine level &gt;1.2 mg/dl, dialysis or previous
             scleroderma renal crisis) involvement

          -  Patients with dyspnea class NYHA &gt;/= II

          -  Patients with palpitations

          -  Patients with bilateral leg edema.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulf Müller-Ladner, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Justus-Liebig-University Gießen, Kerckhoff Clinic, Departement of Rheumatology and Clinical Immunology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gabriele Valentini, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico, Via Pansini, Napoli-Italia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gabriele Valentini, Prof.</last_name>
    <phone>39815464487</phone>
    <email>gabriele.valentini@unina2.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Université Paris Descartes, Hôpital Cochin, Service de Rhumatologie A &amp; INSERM 1016</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yannick Allanore, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Justus-Liebig-University Gießen, Kerckhoff Clinic, Departement of Rheumatology and Clinical Immunology</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ulf Müller-Ladner, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ingo H. Tarner, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Frerix, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin, Charité Centrum 12 für Innere Medizin und Dermatologie, Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gabriela Riemekasten, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Pediatric Rheumatology, Klinikum Eilbek</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ivan Foeldvari, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem - University of Pecs</name>
      <address>
        <city>Pecs</city>
        <zip>H-7622</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laszlo Czirjak, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florence, Denothe Centre, Division of Rheumatology AOUC, Department of Biomedicine</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marco Matucci-Cerinic, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico, Via Pansini</name>
      <address>
        <city>Napoli-Italia</city>
        <zip>5-80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gabriele Valentini, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Felix-Platter Spital, University of Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH 4012</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ulrich Walker, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Zurich, Department of Rheumatology</name>
      <address>
        <city>Zurich</city>
        <zip>8006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Oliver Distler, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Universitiy of Leeds, Division of Rheumatic and Musculoskeletal Disease, St James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francesco Del Galdo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital, University College London</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christopher Denton, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.desscipher.eu</url>
  </link>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 7, 2013</lastchanged_date>
  <firstreceived_date>April 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Second University of Naples</investigator_affiliation>
    <investigator_full_name>Gabriele Valentini</investigator_full_name>
    <investigator_title>Prof. Gabriele Valentini</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Heart Block</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Calcium Channel Blockers</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
